Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2)

نویسندگان

  • Matthias Briel
  • Melanie Lane
  • Victor M Montori
  • Dirk Bassler
  • Paul Glasziou
  • German Malaga
  • Elie A Akl
  • Ignacio Ferreira-Gonzalez
  • Pablo Alonso-Coello
  • Gerard Urrutia
  • Regina Kunz
  • Carolina Ruiz Culebro
  • Suzana Alves da Silva
  • David N Flynn
  • Mohamed B Elamin
  • Brigitte Strahm
  • M Hassan Murad
  • Benjamin Djulbegovic
  • Neill KJ Adhikari
  • Edward J Mills
  • Femida Gwadry-Sridhar
  • Haresh Kirpalani
  • Heloisa P Soares
  • Nisrin O Abu Elnour
  • John J You
  • Paul J Karanicolas
  • Heiner C Bucher
  • Julianna F Lampropulos
  • Alain J Nordmann
  • Karen EA Burns
  • Sohail M Mulla
  • Heike Raatz
  • Amit Sood
  • Jagdeep Kaur
  • Clare R Bankhead
  • Rebecca J Mullan
  • Kara A Nerenberg
  • Per Olav Vandvik
  • Fernando Coto-Yglesias
  • Holger Schünemann
  • Fabio Tuche
  • Pedro Paulo M Chrispim
  • Deborah J Cook
  • Kristina Lutz
  • Christine M Ribic
  • Noah Vale
  • Patricia J Erwin
  • Rafael Perera
  • Qi Zhou
  • Diane Heels-Ansdell
  • Tim Ramsay
  • Stephen D Walter
  • Gordon H Guyatt
چکیده

BACKGROUND Randomized clinical trials (RCTs) stopped early for benefit often receive great attention and affect clinical practice, but pose interpretational challenges for clinicians, researchers, and policy makers. Because the decision to stop the trial may arise from catching the treatment effect at a random high, truncated RCTs (tRCTs) may overestimate the true treatment effect. The Study Of Trial Policy Of Interim Truncation (STOPIT-1), which systematically reviewed the epidemiology and reporting quality of tRCTs, found that such trials are becoming more common, but that reporting of stopping rules and decisions were often deficient. Most importantly, treatment effects were often implausibly large and inversely related to the number of the events accrued. The aim of STOPIT-2 is to determine the magnitude and determinants of possible bias introduced by stopping RCTs early for benefit. METHODS/DESIGN We will use sensitive strategies to search for systematic reviews addressing the same clinical question as each of the tRCTs identified in STOPIT-1 and in a subsequent literature search. We will check all RCTs included in each systematic review to determine their similarity to the index tRCT in terms of participants, interventions, and outcome definition, and conduct new meta-analyses addressing the outcome that led to early termination of the tRCT. For each pair of tRCT and systematic review of corresponding non-tRCTs we will estimate the ratio of relative risks, and hence estimate the degree of bias. We will use hierarchical multivariable regression to determine the factors associated with the magnitude of this ratio. Factors explored will include the presence and quality of a stopping rule, the methodological quality of the trials, and the number of total events that had occurred at the time of truncation.Finally, we will evaluate whether Bayesian methods using conservative informative priors to "regress to the mean" overoptimistic tRCTs can correct observed biases. DISCUSSION A better understanding of the extent to which tRCTs exaggerate treatment effects and of the factors associated with the magnitude of this bias can optimize trial design and data monitoring charters, and may aid in the interpretation of the results from trials stopped early for benefit.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.

OBJECTIVES To investigate the frequency of interim analyses, stopping rules, and data safety and monitoring boards (DSMBs) in protocols of randomized controlled trials (RCTs); to examine these features across different reasons for trial discontinuation; and to identify discrepancies in reporting between protocols and publications. STUDY DESIGN AND SETTING We used data from a cohort of RCT pro...

متن کامل

Randomized trials stopped early for benefit: a systematic review.

CONTEXT Randomized clinical trials (RCTs) that stop earlier than planned because of apparent benefit often receive great attention and affect clinical practice. Their prevalence, the magnitude and plausibility of their treatment effects, and the extent to which they report information about how investigators decided to stop early are, however, unknown. OBJECTIVE To evaluate the epidemiology a...

متن کامل

Stopping guidelines for an effectiveness trial: what should the protocol specify?

BACKGROUND Despite long-standing problems in decisions to stop clinical trials, stopping guidelines are often vague or unspecified in the trial protocol. Clear, well-conceived guidelines are especially important to assist the data monitoring committees for effectiveness trials. MAIN TEXT To specify better stopping guidelines in the protocol for such trials, the clinical investigators and tria...

متن کامل

Experience collecting interim data on mortality: an example from the RALES study

INTRODUCTION: The Randomized Aldactone Evaluation Study (RALES) randomized 822 patients to receive 25 mg spironolactone daily and 841 to receive placebo. The primary endpoint was death from all causes. Randomization began on March 24, 1995; recruitment was completed on December 31, 1996; follow-up was scheduled to continue through December 31, 1999. Evidence of a sizeable benefit on mortality e...

متن کامل

A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials

BACKGROUND Decisions about interim analysis and early stopping of clinical trials, as based on recommendations of Data Monitoring Committees (DMCs), have far reaching consequences for the scientific validity and clinical impact of a trial. Our aim was to evaluate the frequency and quality of the reporting on DMC composition and roles, interim analysis and early termination in pediatric trials. ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Trials

دوره 10  شماره 

صفحات  -

تاریخ انتشار 2009